NEOG
Neogen Corp Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$11.82Close
$2.6BMarket cap
$5.41 – $13.9852-week range
Early-januaryNext report · estimated
Highlights
Strengths
- Leading the market RS 82 · stronger than 82% of stocks over 12 months
- Volume drying up last 10 days 25% under the 50-day average
- Accumulation up-day volume 1.5× down-day volume over 50 sessions
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Earnings shrinking EPS −133% year on year
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
15%
1wk
down 3.0%
price change
1mo
down 7.7%
price change
12-month return
up 97%
market up 11% ·
its own up 79%
F-score
5 / 9
Mixed
Altman Z
1.40
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
1.2×
price / book
Earnings yield
down 0.7%
EBIT / enterprise value
Cheaper than
47%
of the market · around average
Revenue growth
down 3%
year on year
EPS growth
down 133%
latest quarter
Sales growth
up 7%
latest quarter · +7 pts
ROE
0%
return on equity
Free cash margin
up 4%
$31.9M FCF
D/E
0.38
long-term debt / equity
Net debt / EBITDA
6.4×
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- took on more long-term debt
- issued more shares
- gross margin narrowed
- generating cash from operations
- profitability improving
- profits backed by cash
- short-term liquidity improved
- assets working harder
Repair signals
- FCF turned positive ($-46M → $32M)
- Long-term debt down 9% ($0.9B → $0.8B)
Trade setup
ATR%
4.6%
$0.54 a day · 2×ATR $10.73
RS
82 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.5×
vs 50-day average
Up/down volume
1.51
50 sessions
Implied move
—
no scheduled report
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Heavily indebted Net debt is 6.4 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Revenue shrinking Revenue fell 2.7% over the year, from $894.7M to $870.4M.
Last reported
Oct 6, 2026
Results reaction
Oct 6, 2026-11% vs market2 sessions after results
Financials
- Gross 47%
- Net -1%
- Free cash 4%
- Cash
- Long-term debt
| FY2021May 31, 2021 | FY2022May 31, 2022 | FY2023May 31, 2023 | FY2024May 31, 2024 | FY2025May 31, 2025 | FY2026May 31, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $468.5M | $527.2M | $822.4M | $924.2M | $894.7M | $870.4M |
| Gross margin | 46% | 46% | 49% | 50% | 47% | 47% |
| Operating income | $74.2M | $58.6M | $37.5M | $58.6M | -$1.1B | -$21.6M |
| Net income | $60.9M | $48.3M | -$22.9M | -$9.4M | -$1.1B | -$7.9M |
| Net margin | 13% | 9% | -3% | -1% | -122% | -1% |
| Earnings per share | $0.57 | $0.45 | -$0.12 | -$0.04 | -$5.03 | -$0.04 |
| Free cash flow | $54.4M | $43.6M | -$24.7M | -$76.1M | -$46.4M | $31.9M |
| Free cash margin | 12% | 8% | -3% | -8% | -5% | 4% |
| Cash | $75.6M | $44.5M | $163.2M | $170.6M | $129.0M | $185.5M |
| Long-term debt | — | $0 | $885.4M | $888.4M | $874.8M | $793.7M |
| Shareholders' equity | $840.4M | $887.4M | $3.1B | $3.1B | $2.1B | $2.1B |
| Shares outstanding | 107.47m | 107.80m | 216.25m | 217.04m | 217m | 217.70m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 7, 2026 | Quarterly ↗ | Aug 31, 2026 | 37d |
| Jul 30, 2026 | Annual ↗ | May 31, 2026 | 60d |
| Apr 9, 2026 | Quarterly ↗ | Feb 28, 2026 | 40d |
| Jan 8, 2026 | Quarterly ↗ | Nov 30, 2025 | 39d |
| Oct 9, 2025 | Quarterly ↗ | Aug 31, 2025 | 39d |
| Jul 30, 2025 | Annual ↗ | May 31, 2025 | 60d |
| Apr 9, 2025 | Quarterly ↗ | Feb 28, 2025 | 40d |
| Jan 15, 2025 | Quarterly ↗ | Nov 30, 2024 | 46d |
| Oct 10, 2024 | Quarterly ↗ | Aug 31, 2024 | 40d |
| Jul 30, 2024 | Annual ↗ | May 31, 2024 | 60d |
| Apr 9, 2024 | Quarterly ↗ | Feb 29, 2024 | 40d |
| Jan 9, 2024 | Quarterly ↗ | Nov 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 7, 2026 | Shareholder vote ↗ |
| Oct 6, 2026 | Results ↗ |
| Aug 7, 2026 | Director or officer change ↗ |
| Jul 30, 2026 | Results ↗ |
| Apr 20, 2026 | Regulation FD ↗ |
| Apr 9, 2026 | Results ↗ |
| Mar 30, 2026 | Director or officer change ↗ |
| Jan 8, 2026 | Results ↗ |
| Oct 30, 2025 | Director or officer change · Other events ↗ |
| Oct 27, 2025 | Shareholder vote ↗ |
| Oct 9, 2025 | Results ↗ |
| Sep 15, 2025 | Director or officer change · Other events ↗ |